An ultrasensitive immunoassay for the detection of p-tau181 in blood
Yao Chen , Lei Chang, Kaj Blennow, Henrik Zetterberg, Andrew J. Ball

A high-sensitivity blood-based p-tau181 assay could potentially provide a valuable tool for Alzheimer’s disease (AD) research and drug discovery. Based on the recent publication from Karikari et al. [1], this new generation of p-tau181 Simoa™ assay was evaluated for sensitivity, parallelism, cross-reactivity to total tau, spike recovery, and analyte detectability in normal human serum, plasma and CSF and in plasma from Alzheimer’s Disease patients.

Development of an ultrasensitive multiplex assay for simultaneous detection of Aβ1-42, Aβ1-40, GFAP and NF-L in blood and CSF 

Dandan Shan, Marcella Holdridge, Lei Chang, Erik Stoops, Inge M. W. Verberk, Wiesje van der Flier, Charlotte E. Teunissen, Andrew J. Ball

Previous work [1] has described plasma amyloid, GFAP and NF-L as predictors of Alzheimer’s pathology. Here we build on the Amyblood 1-42/1-40 Simoa™ assay [1,2] where GFAP and NF-L, as indicators of astrogliosis and neurodegeneration, further added to the prediction for Aβ PET imaging or diagnosis. We report a Simoa multiplex assay that simultaneously measures Aβ1-42, Aβ1-40, GFAP and NF-L in blood.